Search Results
Your search for Caroline Helwick ,Caroline Helwick matches 2403 pages
Showing 951 - 1000Expert Point of View: Navid Hafez, MD, MPH
Ilixadencel is essentially a dendritic cell vaccine without preloaded antigens. In the MERECA study, ilixadencel produced “a great signal,” though this approach is still very experimental, said the study’s invited discussant, Navid Hafez, MD, MPH, of Yale Cancer Center. Dr. Hafez is a member of the ...
Off-the-Shelf Dendritic Vaccine Shows Benefit in Kidney Cancer
Ilixadencel is a cell-based, allogeneic, off-the-shelf product aimed at priming the anticancer immune response when injected intratumorally. The phase II MERECA study evaluated this allogeneic dendritic cell product given with sunitinib in 88 patients with metastatic renal cell carcinoma. The study ...
Brief Highlights From the 2019 San Antonio Breast Cancer Symposium
In addition to our regular coverage of the 2019 San Antonio Breast Cancer Symposium, the following reports from the meeting include studies you may have missed. We hope you find them of interest. Ribociclib/Letrozole as Neoadjuvant Therapy As neoadjuvant therapy in women with high-risk hormone...
Expert Point of View: Richard L. Schilsky, MD, FACP, FSCT, FASCO
Richard L. Schilsky, MD, FACP, FSCT, FASCO, ASCO’s Chief Medical Officer and a gastrointestinal oncologist himself, was pleased to see the TAPUR study bearing fruit among patients with metastatic colorectal cancer. “Colorectal cancer is a very common disease, but we have not made much progress in...
ASCO’s TAPUR Study: Biomarker-Driven Treatment Paying Off in Colorectal Cancer
New data presented at the 2020 Gastrointestinal Cancers Symposium are validating the purpose of ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) study, a multibasket trial that matches patients’ genomic alterations to commercially available targeted therapies. The aim is to learn...
Expert Point of View: Jarushka Naidoo, MBBCh
“The investigators of the current study tested the hypothesis that vitamin D supplementation is associated with a reduced risk of checkpoint-induced colitis by rigorously assessing 37 variables in both discovery and validation cohorts,” said invited discussant Jarushka Naidoo, MBBCh, Assistant...
Vitamin D Supplementation May Protect Against Checkpoint Inhibitor–Induced Colitis
Vitamin D supplementation prior to starting immune checkpoint inhibitor therapy may significantly reduce the odds of developing colitis, according to a study conducted at Harvard Medical School. Although this was a retrospective chart review, the association was relatively strong in the...
Former FDA Commissioner Scott Gottlieb, MD, Relays Opinions on Coronavirus
Scott Gottlieb, MD, former Commissioner of the U.S. Food and Drug Administration (FDA), had some advice for attendees of the 37th Annual Miami Breast Cancer Conference in his keynote address at the meeting. While his formal presentation pertained to innovations in oncology drug development and...
Expert Point of View: Daniel V.T. Catenacci, MD
Daniel V.T. Catenacci, MD, Associate Professor of Medicine and Director of the Gastrointestinal Oncology Program at the University of Chicago, was the JAVELIN Gastric 100 study’s invited discussant. After offering an extensive background on the use of immunotherapy in gastric or gastroesophageal...
No Survival Benefit for Maintenance Avelumab in Advanced Gastric or Gastroesophageal Junction Cancer
In the phase III JAVELIN Gastric 100 trial, a strategy called “switch maintenance” with the immune checkpoint inhibitor avelumab after 12 weeks of first-line induction chemotherapy did not statistically improve overall survival for treatment-naive patients with HER2-negative advanced gastric or...
New POLO Data Further Support Maintenance Olaparib in BRCA1/2-Positive Pancreatic Cancer
In posters presented at the 2020 Gastrointestinal Cancers Symposium, POLO investigators reported that health-related quality of life was preserved during maintenance olaparib in patients with BRCA 1/2-positive pancreatic cancer, as evidenced by a low symptom burden over time.1 Other studies...
Automated Referral Process for Genetic Counseling and Testing of Patients With Pancreatic Cancer
Routine genetic counseling and multigene testing of patients with pancreatic cancer result in the detection of mutations that are actionable, not only for patients, but also for at-risk family members. At the Dana-Farber Cancer Institute, the use of a systemized, automated referral system that does ...
Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients
As the number of solid organ transplants in the United States rises, cancer in this patient population is a growing concern. In fact, solid organ transplant recipients have an up to 50 times greater risk than the general population of developing skin cancers, and for kidney transplant recipients,...
Expert Point of View: Kevin Kalinsky, MD, MS
Commenting on SAFIR02-IMMUNO for The ASCO Post, Kevin Kalinsky, MD, MS, Associate Professor of Medicine at NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, said the findings of the analysis were in accordance with other studies in metastatic breast cancer, but they came...
Mixed Results With Durvalumab Maintenance in HER2-Negative Advanced Breast Cancer
Given as maintenance therapy, the checkpoint inhibitor durvalumab significantly improved overall survival in patients with metastatic triple-negative breast cancer and yielded a numerical but not significant benefit as well for patients expressing programmed cell death ligand 1 (PD-L1), in...
Expert Point of View: George A. Fisher, Jr, MD, PhD
George A. Fisher, Jr, MD, PhD, the Colleen Haas Chair in Medicine-Oncology at Stanford University School of Medicine, commented on the cell-free DNA methylation blood-based test from the Circulating Cell-Free Genome Atlas (CCGA) study. The findings presented by Dr. Wolpin, he said, “lead us to the ...
Use of Cell-Free DNA Methylation–Based Blood Test in Detecting Gastrointestinal Cancers
A noninvasive, blood-based, cell-free DNA test focused on the presence of DNA methylation appears to be highly sensitive in detecting gastrointestinal cancers and may pinpoint the tissue of origin in the vast majority of these cancers.1 The assay was developed based on findings from the...
Expert Point of View: A. Craig Lockhart, MD
The invited discussant of the IMbrave150 trial, A. Craig Lockhart, MD, Professor of Medicine, University of Miami Sylvester Comprehensive Cancer Center, applauded the study for making patient-reported outcomes a prespecified endpoint and described the value of having this information. “The U.S....
Patient-Reported Outcomes From IMbrave150: Better Quality of Life With Doublet
For the first-line treatment of advanced hepatocellular carcinoma, atezolizumab plus bevacizumab provided a significant overall survival benefit in the pivotal IMbrave150 trial. New findings from a prespecified analysis also showed numerous benefits for the doublet in terms of quality of life,...
Expert Point of View: Suzanne Lentzsch, MD, PhD
Suzanne Lentzsch, MD, PhD, Professor of Medicine and Director of the Multiple Myeloma and Amyloidosis Service at Columbia University, offered her thoughts on venetoclax-based regimens, such as the one described by Dr. Kaufman. “Despite tremendous progress in the treatment of multiple myeloma, the...
Venetoclax Plus Dexamethasone Shows Activity in t(11;14) Multiple Myeloma
In a phase I/II study of patients with advanced multiple myeloma and t(11;14) translocations, the combination of venetoclax and dexamethasone showed strong, durable activity, even in patients refractory to daratumumab, study investigators reported at the 2019 American Society of Hematology (ASH)...
Expert Point of View: Basem M. William, MD, MRCP
Basem M. William, MD, MRCP, Director of the T-Cell Lymphoma Program and Cutaneous Lymphoma Multidisciplinary Clinic at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, commented on the newly reported findings...
Strong Activity Shown for Lisocabtagene Maraleucel CAR T-Cell Therapy in Aggressive Large B-Cell Lymphoma
Another CD19-directed chimeric antigen receptor (CAR) T-cell therapy may be poised to enter the marketplace for aggressive relapsed or refractory large B-cell lymphoma, based on a high rate of rapid and durable complete responses achieved with lisocabtagene maraleucel. The phase I TRANSCEND NHL...
Expert Point of View: Christopher M. Booth, MD
Patients with BRAF-mutated metastatic colorectal cancer “pose clinical challenges for us every day,” said Christopher M. Booth, MD, Professor of Medical Oncology and the Canada Research Chair in Population Cancer Care at Queen’s University, Kingston, Ontario, the invited discussant of the...
BEACON-CRC: Quality of Life May Be Well Maintained With Targeted Treatment
For patients with previously treated metastatic colorectal cancer harboring BRAF V600E mutations, the phase III BEACON-CRC study showed the benefit for combining two or three targeted agents vs the standard of care.1 The study has now also shown a benefit for the triplet and doublet in maintaining ...
Expert Point of View: Andrea Wang-Gillam, MD, PhD
Andrea Wang-Gillam, MD, PhD, Clinical Director of the GI Oncology Program and Director of Developmental Therapeutics at Washington University in St. Louis, was the invited discussant of SEQUOIA and HALO 109-301. She tried to make sense of the two negative studies of pegylated agents in advanced...
Two Novel Pegylated Agents Fail in Metastatic Pancreatic Cancer
Two novel treatments once thought to hold promise in the treatment of metastatic pancreatic cancer have not proved to be effective in phase III trials, investigators reported at the 2020 Gastrointestinal Cancers Symposium. When combined with standard chemotherapy, a pegylated form of human...
Expert Point of View: Edmund K. Waller, MD, PhD
Edmund K. Waller, MD, PhD, Professor, Departments of Medicine, Pathology, and Hematology and Medical Oncology at Emory University School of Medicine and Medical Director, Center for Stem Cell Processing and Apheresis at Emory, said he was not surprised to learn that bridging therapy was associated...
Study Finds ‘Bridge’ to CAR T-Cell Therapy May Be Detrimental to Survival
The use of bridging therapy before treatment with axicabtagene ciloleucel was associated with worse overall survival in univariate, multivariate, and propensity score–matched analyses performed on data from the U.S. Lymphoma CAR T Consortium, investigators reported at the 2019 American Society of...
Expert Point of View: Marcia Cruz-Correa, MD, PhD
Marcia Cruz-Correa, MD, PhD, Professor of Medicine at the University of Puerto Rico and Adjunct Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center, congratulated the investigators on the conduct of the PANGEA trial and the outcomes it achieved for patients. “When...
PANGEA Trial Shows Personalized Antibody Selection May Improve Outcomes in Gastroesophageal Cancer
A personalized approach to selecting antibody therapy for patients with newly diagnosed stage IV gastroesophageal adenocarcinoma resulted in a 1-year overall survival rate of 66% and a median overall survival of 16.4 months in the PANGEA study (see Table 1).1 The study used a novel clinical...
Expert Point of View: Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH, Assistant Professor of Medicine at Harvard Medical School and Associate Director of the Susan F. Smith Center for Women’s Cancers at Dana-Farber/Brigham and Women’s Cancer Center, Boston, commented on KEYNOTE-890. “Previous work has suggested minimal activity of...
Triple-Negative Breast Cancer Responds to Novel Therapy
The phase II KEYNOTE-890 trial is a small but interesting study in patients with inoperable advanced triple-negative breast cancer. After one injection of intratumoral tavokinogene telseplasmid, a plasmid encoding the proinflammatory cytokine interleukin-12 (IL-12), followed by electroporation and...
Expert Point of View: Jeremy S. Abramson, MD
Jeremy S. Abramson, MD, Director of the Jon and JoAnn Hagler Center for Lymphoma at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, Boston, commented on the study by Topp et al for The ASCO Post. “Earlier use of steroids with axicabtagene ciloleucel...
Early Steroid Use May Reduce Toxicity With CAR T-Cell Therapy
In patients with large B-cell lymphoma undergoing chimeric antigen receptor (CAR) T-cell therapy with axicabtagene ciloleucel, earlier-than-usual intervention with corticosteroids and tocilizumab may reduce the incidence of severe cytokine-release syndrome, according to the findings of a...
Expert Point of View: Basem M. William, MD, MRCP(UK), FACP
Basem M. William, MD, MRCP(UK), FACP, Director of the T-Cell Lymphoma Program and Member of the Blood and Marrow Transplant Program at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, commented on the...
CAR T-Cell Therapy Comes to Mantle Cell Lymphoma
Advanced mantle cell lymphoma appears to be a good target for chimeric antigen receptor (CAR) T-cell therapy. Treatment with KTE-X19, an anti-CD19 CAR T-cell product, led to unprecedented outcomes in patients with relapsed or refractory disease in the phase II ZUMA-2 study presented at the 2019 ASH ...
Expert Point of View: Richard L. Schilsky, MD, FACP, FSCT, FASCO
Richard L. Schilsky, MD, FACP, FSCT, FASCO, Chief Medical Officer and Executive Vice President of ASCO, who is also a gastrointestinal oncologist, called the 74% response rate to cisplatin/gemcitabine “remarkable.” “What’s impressive to me is the high response rate, as well as the progression-free ...
‘Unprecedented’ Responses to Cisplatin/Gemcitabine in BRCA-Mutated Advanced Pancreatic Cancer
As first-line treatment of patients with pancreatic ductal adenocarcinoma and a germline BRCA/PALB2 mutation, cisplatin plus gemcitabine yielded high response rates and encouraging survival, establishing this doublet as a standard approach in this subset of patients, according to Eileen M....
Expert Point of View: Virginia Kaklamani, MD, Steven Vogl, MD, Gary Lyman, MD, MPH, and Ginny Mason, BSN
For several breast cancer experts interviewed by The ASCO Post, the phase III oral paclitaxel study and the drug itself had some limitations. Virginia Kaklamani, MD, of UT Health San Antonio, moderator of a press briefing, thought that the dosing process and the 11 pills or so per day was a...
Expert Point of View: Charles L. Shapiro, MD
Charles L. Shapiro, MD, Professor of Medicine, Hematology and Oncology at the Icahn School of Medicine at Mount Sinai, New York, commented on the Women’s Health Initiative update. “These trials involved more than 27,000 women between the ages of 50 and 79. The women with a uterus were randomly...
Oral Paclitaxel Outperforms Intravenous Formulation in Phase III Trial
In the first reported phase III study of an oral taxane, an investigational oral form of paclitaxel yielded a higher overall response rate and produced less neuropathy than standard intravenous paclitaxel, researchers reported at the 2019 San Antonio Breast Cancer Symposium.1 “Oral paclitaxel...
Studies Find Estrogen Alone Protective, Estrogen Plus Progestin Detrimental in Postmenopausal Women
In postmenopausal women without prior breast cancer, estrogen alone reduced the risk of breast cancer, not only during treatment, but for years after estrogen was stopped. It also reduced deaths as a result of breast cancer and deaths after breast cancer from all causes. However, in contrast,...
Expert Point of View: Shelley Hwang, MD, MPH
Shelley Hwang, MD, MPH, the Mary and Deryl Hart Distinguished Professor of Surgery, Duke University School of Medicine in North Carolina, discussed the APBI IMRT Florence trial in a meeting highlights session at the San Antonio Breast Cancer Symposium. She called physician-reported cosmesis “the...
Partial-Breast Irradiation Favored Over Whole-Breast in Early Breast Cancer
Patients with early breast cancer with small, node-negative tumors can safely be treated with accelerated partial-breast irradiation using intensity-modulated radiotherapy. According to the 10-year median follow-up of the randomized phase III APBI IMRT Florence trial, recurrence rates were low and...
Expert Point of View: Debra A. Patt, MD, MPH, MBA, FASCO, and C. Kent Osborne, MD, FASCO
Debra A. Patt, MD, MPH, MBA, FASCO, Clinical Professor at Dell Medical School at The University of Texas at Austin and Executive Vice President of Public Policy and Strategy Initiatives for Texas Oncology, told attendees in a symposium highlights talk, “We all identify and follow some patients who ...
Breast Cancer Chemoprevention Effect Maintained Long After Stopping Anastrozole Therapy
For postmenopausal women at high risk for developing breast cancer—largely based on family history—anastrozole taken for 5 years maintained a preventive effect for at least an additional 7 years after stopping the drug in the IBIS-II trial, which included nearly 4,000 subjects. Women randomly...
Expert Point of View: Hope S. Rugo, MD, FASCO, and Laura J. Esserman, MD, MBA, FASCO
Hope S. Rugo, MD, FASCO, Professor of Medicine, Director of Breast Oncology and Clinical Trials at the University of California, San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, said the residual cancer burden index is being increasingly used in medical oncology. “The...
Residual Cancer Burden Is Prognostic of Outcomes Across Breast Cancer Subtypes
Residual cancer burden after neoadjuvant chemotherapy can accurately predict disease recurrence and survival across all breast cancer subtypes, according to the findings from a meta-analysis presented at the 2019 San Antonio Breast Cancer Symposium by W. Fraser Symmans, MD, Professor and Director...
Expert Point of View: Debra Patt, MD, MPH, MBA
Debra Patt, MD, MPH, MBA, Executive Vice President of Policy and Strategy for Texas Oncology and Clinical Professor at Dell Medical School at the University of Texas at Austin, commented that the 10-year results of NSABP B-42 show “a substantial improvement” in disease-free survival, with an...
